Sobi Global
OUR SCIENCE | R&D Innovative medicines in the pipeline Only 5 % of rare diseases have approved medicines. The need for innovative treatments is, therefore, high. A strong pipeline and expanded access are key elements of our commitment to patients. View pipeline RESULTS CENTRE Interim Report Q1 2025Sobi published Q1 2025 report on 29 April.Report WebcastPresentationAnnual General Meeting 2025The AGM was held on Thursday, 8 May 2025.Read more MEDIA | PRESS RELEASES Press releases 8 May, 2025 11:30 Bulletin from Sobi's Annual General Meeting (AGM) 29 April, 2025 08:00 Sobi publishes Q1 2025 report: Portfolio continues to deliver Learn more
Total Visits
Avg. Visit Duration
Pages per Visit
Bounce Rate
Registration Date
| Month | Traffic |
|---|---|
| 2025-02 | 51.804 |
| 2025-03 | 46.562 |
| 2025-04 | 54.296 |
| 2025-05 | 78.91 |
| Source | Traffic Share |
|---|---|
| search | 55.51% |
| direct | 31.31% |
| referrals | 8.12% |
| social | 3.81% |
| paid referrals | 0.77% |
| 0.12% |
| Region | Percentage |
|---|---|
| United States | 25.55% |
| CH | 16.60% |
| Germany | 9.28% |
| SE | 6.11% |
| Keyword | Traffic | Volume | CPC |
|---|---|---|---|
| sobi | 1,148 | 11,480 | $0.92 |
| sobi company basel | 0 | 0 | $0.00 |
| swedish orphan biovitrum | 104 | 1,040 | $0.00 |
| sobi - swedish orphan biovitrum ab (publ) share show more options analytical science & technology specialist | 0 | 0 | $0.00 |
| who owns sobi pharmaceuticals? | 5 | 50 | $0.00 |